A particular monoclonal antibody.

(pharmacology) A fusion protein composed of an immunoglobulin fused to the extracellular domain of CTLA-4, a molecule capable of binding B7, used to treat rheumatoid arthritis.

(pharmacology) A powerful anticlotting drug (trademark ReoPro) that inhibits platelet aggregation by binding to a glycoprotein receptor on human platelets and that consists of the F_(ab) fragment from a chimeric monoclonal antibody prepared from humans and mice.

(pharmacology) A humanized monoclonal antibody developed in an attempt to prevent bone lesion metastases in castration-resistant prostate cancer.

(pharmacology) An immunosuppressive drug (trademark Humira) that is a genetically engineered monoclonal antibody administered by subcutaneous injection to treat the symptoms of various autoimmune diseases (such as rheumatoid arthritis, Crohn's disease, and psoriasis). It acts by binding to and blocking the activity of tumor necrosis factor.

(pharmacology) A recombinant monoclonal antibody used to target tumour cells.

(pharmacology) A human monoclonal antibody and drug candidate designed for treatment of Alzheimer's disease.

A monoclonal antibody that reduces the concentration of interleukin-6 in patients with sepsis.

A fusion protein under development for the treatment of cancer.

A monoclonal antibody against CD20, used to treat lymphoma.

(immunology) A monoclonal antibody that aims to boost the human immune system either to fight infection or cancer.

(pharmacology) A monoclonal antibody used as an antineoplastic.

A recombinant fusion protein drug consisting of interferon alpha (IFN-α) linked to human albumin.

A particular therapeutic interleukin.

(pharmacology) A monoclonal antibody used in the treatment of chronic lymphocytic leukemia and T-cell lymphoma, targeting CD52.

(pharmacology) A human monoclonal antibody used to treat high cholesterol.

A mouse monoclonal antibody used to diagnose colorectal cancer.

(pharmacology) A chimeric monoclonal antibody designed for the treatment of cancer.

A monoclonal antibody used to treat some lung cancers

(pharmacology) A drug that blocks the activity of interleukin-1 and is administered as a subcutaneous injection chiefly in the treatment of rheumatoid arthritis. It is a recombinant form of an endogenous antagonist of interleukin-1 receptor and is marketed under the trademark Kineret.

A mouse monoclonal antibody used to treat non-small-cell lung cancer.

A monoclonal antibody that blocks certain interferon activity, used to treat systemic lupus erythematosus.

(pharmacology) A humanized monoclonal antibody designed for the treatment of asthma.

(pharmacology) A humanized monoclonal antibody being studied as a treatment for hematologic cancers.

(pharmacology) A monoclonal antibody used to detect carcinoembryonic antigen.

(pharmacology) Used in the names of monoclonal antibodies, indicating that they are linked to an A chain of the ricin protein.

A recombinant fusion protein designed to inhibit B cells, thereby suppressing autoimmune disease.

(pharmacology) An monoclonal antibody used in immunotherapy.

(pharmacology) An immunomodulator that binds to reticulon-4.

(pharmacology) Tocilizumab.

A monoclonal antibody used in the combination drug atoltivimab/maftivimab/odesivimab to treat Zaire ebolavirus.

(pharmacology) An immunosuppressive drug directed against the Rhesus factor.

(medicine) An antibody used to treat covid infections

(medicine) A monoclonal antibody used against some carcinomas

(pharmacology) A neutralising monoclonal antibody directed against the spike protein of SARS-CoV-2.

(pharmacology) A humanized monoclonal antibody that acts on the nervous system and has potential therapeutic value for the treatment of Alzheimer's disease and possibly glaucoma.

(pharmacology) A monoclonal antibody used to prevent rejection in organ transplantation, especially in kidney transplants.

(pharmacology) A chimeric monoclonal antibody with potential applications in the treatment of cancers and viral infections.

A monoclonal antibody used to detect non-Hodgkin's lymphoma.

A monoclonal antibody used as a medication for the treatment of relapsed and refractory multiple myeloma

A fusion protein, similar to abatacept, used to improve graft survival after transplantation.

(pharmacology) A human monoclonal antibody that inhibits the biological activity of B-lymphocyte stimulator (BLyS).

(pharmacology) A monoclonal antibody being developed for the treatment of asthma.

(pharmacology) A human monoclonal antibody that binds to eotaxin 1.

A mouse monoclonal antibody used to detect inflammatory lesions and metastases.

(pharmacology) An anticancer drug that is a genetically engineered monoclonal antibody administered intravenously to slow or inhibit tumor growth especially in some metastatic forms of cancer (such as colorectal cancer). It acts by binding to and inhibiting the activity of vascular endothelial growth factor, a protein that promotes the growth of new blood vessels which supply a spreading tumor. It is marketed under the trademark Avastin.

(pharmacology) A particular monoclonal antitoxin antibody

A particular mouse monoclonal antibody.

A monoclonal antibody used to treat muscle loss

A treatment for psoriasis

(pharmacology) A particular humanized monoclonal antibody.

A particular fusion protein with anticancer properties.

A selective antagonist of B-cell activating factor, under development as a treatment for systemic lupus erythematosus.

A monoclonal antibody no longer used

A proteasome inhibitor used in cancer treatment and chemotherapy.

A human monoclonal antibody designed for the treatment of Crohn's disease

(pharmacology) An antibody used in certain drugs.

an antibody-drug conjugate (ADC), directed to the protein CD30 and used in cancer treatment

(pharmacology) A human monoclonal antibody being developed to treat rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis.

(pharmacology) A human monoclonal antibody designed to treat inflammatory diseases such as psoriasis.

(pharmacology) A particular monoclonal antibody.

(pharmacology) A particular anticancer drug.

(pharmacology) A human monoclonal antibody targeted at interleukin-1 beta, intended to treat rheumatoid arthritis.

(pharmacology) A humanized monoclonal antibody used to treat colorectal cancer.

A monoclonal antibody used to counter thrombosis

A mouse monoclonal antibody used to image the extent of prostate cancer.

A mouse monoclonal antibody used to image the extent of prostate cancer.

(medicine) A drug, that inhibits ubiquitination, used for the treatment of multiple myeloma

(pharmacology) A human monoclonal antibody designed for oncology and immune indications.

(medicine) A monoclonal antibody used together with imdevimab to treat Covid-19

Cambridge Antibody Technology

A rat-murine hybrid monoclonal antibody used to treat certain cancers.

a cell membrane protein of the tumor necrosis factor receptor family, serving as a tumor marker and the target of brentuximab vedotin

a cell surface protein that is used as a marker of plasma cells, targeted by elotuzumab.

a peptide of 12 amino acids, associated with certain types of lymphoma and targeted by alemtuzumab.

(pharmacology) A monoclonal antibody that acts on the immune system and may have applications in preventing organ transplant rejections and in treating autoimmune diseases.

A monoclonal antibody used to treat some skin cancers

A synthetic monoclonal antibody

(pharmacology) A particular monoclonal antibody used in the treatment of Crohn's disease.

(pharmacology) A chimeric (mouse/human) monoclonal antibody that targets epidermal growth factor receptor.

A particular bispecific monoclonal antibody

A monoclonal antibody fused with bouganin that has undergone preclinical trials for the treatment of ovarian cancer and other solid tumours.

(pharmacology) A monoclonal antibody used in the treatment of solid tumours.

(pharmacology) An investigational drug, an aglycosylated, humanized rabbit monoclonal antibody against interleukin-6.

(pharmacology) A chimeric monoclonal antibody that acts as an immunomodulator.

(pharmacology) A human monoclonal antibody used to treat cancer.

(pharmacology) A humanized monoclonal antibody being investigated as a treatment of Alzheimer's disease.

(pharmacology) A humanized monoclonal antibody under development for the treatment of certain cancers.

(pharmacology) A humanized monoclonal antibody used to prevent rejection in organ transplantation, especially in kidney transplants.

(pharmacology) A humanized monoclonal antibody designed for the treatment of cancers.

(pharmacology) A drug (trademark Prolia and Xgera) that is a genetically engineered monoclonal antibody that reduces bone resorption and increases bone mass by inhibiting osteoclast formation and function and that is administered by injection to prevent fractures associated with osteoporosis and malignant tumors of bone and to treat hypercalcemia associated with various cancers.

An antibody drug used to treat breast cancer

A mouse monoclonal antibody developed for the treatment of cancer.

(pharmacology) A particular monoclonal antibody

A monoclonal antibody used as an immunosuppressive drug.

A monoclonal antibody used to treat endometrial cancer.

(pharmacology) A human monoclonal antibody designed for the treatment of cancers.

(medicine, biochemistry) A recombinant protein used to treat some cancers

A monoclonal antibody used to treat some cancers

(pharmacology) A monoclonal antibody designed for the treatment of allergic diseases such as eczema.

(pharmacology) A monoclonal antibody that is an antineoplastic drug

(pharmacology) A chimeric monoclonal antibody being developed for the treatment of malignant melanoma.

(pharmacology) A monoclonal antibody directed against the complement protein C5.

A mouse monoclonal antibody that was investigated as a possible treatment for sepsis caused by Gram-negative bacterial infections.

A chimeric monoclonal antibody with possible applications in treating cancers.

(pharmacology) A recombinant humanized monoclonal antibody, formerly available to treat autoimmune diseases, especially psoriasis, by binding CD11a of lymphocyte function-associated antigen 1, and associated with fatal brain infections.

(pharmacology) A human monoclonal antibody intended to treat invasive Candida infection in combination with amphotericin B.

(pharmacology) A humanized monoclonal antibody.

A mouse monoclonal antibody used as an immunosuppressive drug.

(pharmacology) A chimeric bispecific antibody used in the treatment of haemophilia.

(pharmacology) A chimeric monoclonal antibody used in the treatment of cancers.

(pharmacology) A humanized monoclonal antibody with potential applications in oncology and in the treatment of inflammatory autoimmune disorders such as lupus.

A monoclonal antibody medication for the preventive treatment of migraine in adults.

(pharmacology) A recombinant humanized monoclonal antibody developed to treat heart attack, stroke, and traumatic shock.

A rat-murine hybrid monoclonal antibody used to treat certain cancers.

(pharmacology) A protein drug that binds to and blocks the action of tumor necrosis factor and is administered by injection to treat various inflammatory diseases (such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis). It is a dimeric protein consisting of the ligand-binding portion of a human receptor for tumor necrosis factor linked to the basal, heavy chain, portion of IgG which determines the immune response to bound antigen. It is produced by recombinant DNA technology using hamster ovary cells and is marketed under the trademark Enbrel.

(pharmacology) A humanized monoclonal antibody being investigated for the treatment of metastatic melanoma and various cancers.

A monoclonal antibody used with bamlanivimab

A monoclonal antibody used as a drug to treat homozygous familial hypercholesterolemia.

(pharmacology) A human monoclonal antibody designed for the treatment of hyperlipidemia.

(pharmacology) A human monoclonal antibody developed for the treatment of hepatitis B.

A mouse monoclonal antibody formerly used to aid in the diagnosis of appendicitis.

A mouse monoclonal antibody used as an immunomodulator.

(medicine) An antibody used to treat macular degeneration.

(pharmacology) A monoclonal antibody being investigated for the treatment of ovarian cancer.

A human monoclonal antibody designed for the treatment of acute sciatic pain.

(pharmacology) A humanized monoclonal antibody directed against the Human respiratory syncytial virus.

(pharmacology) A human monoclonal antibody against interleukin-22, designed for the treatment of psoriasis and rheumatoid arthritis.

(pharmacology) A monoclonal antibody under investigation for the treatment of various cancers.

(pharmacology) A monoclonal antibody designed for the treatment of rheumatoid arthritis.

(pharmacology) A humanized monoclonal antibody used as an immunomodulator.

(pharmacology) A human monoclonal antibody for the prophylaxis of rabies.

A monoclonal antibody used to treat migraine

(pharmacology) A human monoclonal antibody and immunomodulator under investigation for the treatment of idiopathic pulmonary fibrosis, focal segmental glomerulosclerosis, and cancer.

A felinized monoclonal antibody used to treat osteoarthritis in cats.

A monoclonal antibody against nerve growth factor, designed for the treatment of pain.

}(pharmacology) A monoclonal antibody used to treat migraine.

(pharmacology) A chimeric monoclonal antibody designed for the treatment of B-cell lymphoma.

An engineered fragment of a chicken antibody used to counter Mycobacterium bovis

(pharmacology) A human monoclonal antibody against type 1 insulin-like growth factor receptor, designed for the treatment of cancers.

(pharmacology) A monoclonal antibody used as an immunomodulator in the treatment of Alzheimer's disease.

A mouse monoclonal antibody for the treatment of glucocorticoid-resistant graft-versus-host disease.

an monoclonal antibody targeting CD33, having a cytotoxic calicheamicin-class agent attached, which was used to treat acute myelogenous leukemia until withdrawn out of lethal toxicity

(pharmacology) A particular monoclonal antibody.

A particular human monoclonal antibody

(pharmacology) A genetically engineered monoclonal antibody (trademark Simponi) that inhibits the activity of tumor necrosis factor and is administered by subcutaneous injection to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.

A chimeric monoclonal antibody used as an immunosuppressive drug in the treatment of allergic asthma.

A recombinant monoclonal antibody that has some immunosuppressive activity

(oncology) Receptor which is the target for the drug trastuzumab in chemotherapy.

Alternative spelling of HER-2 [(oncology) Receptor which is the target for the drug trastuzumab in chemotherapy.]

anti-NCAM immunotoxine showing activity against small cell lung cancer

(immunology) A hybrid cell engineered from a lymphocyte and a tumour cell; used to generate monoclonal antibodies

(pharmacology) A nonimmunosuppressive monoclonal antibody being investigated as an HIV entry inhibitor.

A monoclonal antibody which is linked with yttrium-90 as the drug ibritumomab tiuxetan

A monoclonal antibody radioimmunotherapy treatment for some forms of B-cell non-Hodgkin lymphoma.

(pharmacology) A monoclonal antibody designed for the reversal of anticoagulant effects of dabigatran.

immunoglobulin heavy chain variable region gene, mutations of which in B-cell neoplasms like chronic lymphocytic leukemia are associated with better responses to some treatments and with prolonged survival

A mouse monoclonal antibody for the diagnosis of ovarian cancer that is no longer available.

A mouse monoclonal antibody formerly used for cardiac imaging.

A monoclonal antibody used with casirivimab to treat COVID-19

(medicine) The fusion of an antibody and a cytokine used in cancer therapy

an immunomodulator and antineoplastic antibody-drug conjugate, consisting of anti-CD138 linked to the maytansinoid DM4, targeting various solid tumors and hematological malignancies like multiple myeloma

A medication for the treatment of neuromyelitis optica spectrum disorder.

(pharmacology) An immunosuppressive drug (trademark Remicade) administered by intravenous injection especially to treat the symptoms of Crohn's disease, ulcerative colitis, and rheumatoid arthritis. It is a chimeric monoclonal antibody prepared from humans and mice that acts by binding to and blocking the activity of tumor necrosis factor.

A mouse monoclonal antibody developed as an immunosuppressive drug against graft-versus-host disease.

(medicine) A monoclonal antibody used to treat some cancers

A humanized monoclonal antibody for the treatment of cancers.

(pharmacology) A particular human monoclonal antibody.

(pharmacology) A human monoclonal antibody being developed as a drug to activate the immune system.

(pharmacology) A human monoclonal antibody used in the treatment of oncological diseases.

A monoclonal antibody medication for the treatment of multiple myeloma.

(pharmacology) A particular interleukin-1 receptor inhibitor.

A recombinant monoclonal antibody proposed for the treatment of covid

(pharmacology) A humanized monoclonal antibody for the treatment of autoimmune diseases. It works by binding to interleukin 17 and blocking its action.

(pharmacology) A chimeric monoclonal antibody used in treating severe chronic asthma.

(pharmacology) A humanized monoclonal antibody for the treatment of colorectal cancer.

The drug pembrolizumab.

A human monoclonal antibody used in the treatment of muscular disorders

An experimental immunomodulator being investigated as an oral treatment for multiple sclerosis.

(pharmacology) A humanized monoclonal antibody and immunosuppressive drug being investigated for the treatment of asthma.

A mouse monoclonal antibody for the diagnosis of inflammatory lesions.

(pharmacology) A human monoclonal antibody and immunosuppressive drug developed to reduce scarring after glaucoma drainage surgery.

A monoclonal antibody proposed as a treatment for COVID-19

(pharmacology) An agonistic human monoclonal antibody used to treat cancer.

(pharmacology) A human monoclonal antibody directed against the Hepatitis B virus.

(pharmacology) A humanized monoclonal antibody used to treat cancer.

(medicine) A monoclonal antibody conjugate medication used to treat large B-cell lymphoma.

(pharmacology) A human monoclonal antibody being investigated for the treatment of various cancers.

(pharmacology) A chimeric monoclonal antibody being investigated for the treatment of chronic lymphocytic leukemia.

Abbreviation of monoclonal antibody. [(medicine) A protein genetically engineered from a single clone of a B cell, especially one produced by fusion with a tumor cell and intended for use as a drug.]

A monoclonal antibody used in the combination drug atoltivimab/maftivimab/odesivimab to treat Zaire ebolavirus.

(pharmacology) A human monoclonal antibody used in the treatment of cancer.

A chimeric IgG monoclonal antibody medication against HER2, designed for the treatment of cancer.

A mouse monoclonal antibody and immunosuppressive drug.

(pharmacology) A humanized monoclonal antibody used to treat cancer.

(pharmacology) A human monoclonal antibody for the treatment of rheumatoid arthritis.

(pharmacology) A humanized monoclonal antibody that recognizes interleukin-5 and is used to treat certain kinds of asthma and white blood cell diseases.

A chelator used to attach the antibody nofetumomab to a radioisotope of technetium.

(pharmacology) A human monoclonal antibody intended for the treatment of scleroderma but later dropped in favour of alternatives.

(pharmacology) A monoclonal antibody intended to treat multiple myeloma and other hematological malignancies.

A mouse monoclonal antibody designed to treat cancer.

A mouse monoclonal antibody being investigated for the treatment of small-cell lung carcinoma.

Abbreviation of monoclonal antibody. [(medicine) A protein genetically engineered from a single clone of a B cell, especially one produced by fusion with a tumor cell and intended for use as a drug.]

(pharmacology) A humanized monoclonal antibody used to treat adult T-cell leukemia/lymphoma.

(pharmacology) An investigational drug for the treatment of rheumatoid arthritis, gynecologic malignancies and other cancers.

(immunochemistry) something produced from a single clone, especially a monoclonal antibody

(medicine) A protein genetically engineered from a single clone of a B cell, especially one produced by fusion with a tumor cell and intended for use as a drug.

(pharmacology) A human monoclonal antibody against the human Rhesus factor.

A monoclonal antibody under investigation for the treatment of follicular lymphoma.

(pharmacology) A humanized monoclonal antibody being investigated for the prevention of respiratory syncytial virus infection in high-risk infants.

(pharmacology) A monoclonal antibody.

A mouse monoclonal antibody designed for the treatment of colorectal cancer.

A human monoclonal antibody for use against arthritis

A monoclonal antibody being developed for the treatment of various cancers.

(pharmacology) A humanized monoclonal antibody used in the treatment of multiple sclerosis and Crohn's disease.

A monoclonal antibody medication used to treat certain forms of neuroblastoma.

(pharmacology) A human monoclonal antibody developed for the treatment of sepsis but later withdrawn.

(pharmacology) A monoclonal antibody and antineoplastic that binds to EGFR, under investigation for the treatment of cancer.

A mouse monoclonal antibody that acts as a TNF inhibitor.

(pharmacology) A monoclonal antibody used to treat squamous cell carcinoma, head and neck cancer, nasopharyngeal cancer, and glioma.

(pharmacology) a human IgG4 anti-PD-1 monoclonal antibody, acting as a checkpoint inhibitor, thus allowing activated T cells to attack cancer cells

A monoclonal antibody used to diagnose certain cancers.

(pharmacology) Synonym of afutuzumab.

(pharmacology) A humanized monoclonal antibody with possible applications as an immunosuppressive drug.

A monoclonal antibody used in the combination drug atoltivimab/maftivimab/odesivimab to treat Zaire ebolavirus.

(pharmacology) A human monoclonal antibody targeting CD20, under investigation for the treatment of chronic lymphocytic leukemia and other diseases.

(pharmacology) A particular monoclonal antibody.

A human monoclonal antibody used to treat certain cancers

A particular anti-inflammatory monoclonal antibody

(pharmacology) A humanized monoclonal antibody designed to treat cancer.

A monoclonal antibody used as an antineoplastic.

A mouse monoclonal antibody designed to treat ovarian cancer.

A monoclonal antibody being developed for the treatment of type 1 diabetes and other autoimmune diseases.

(pharmacology) Any of a certain group of monoclonal antibodies.

A monoclonal antibody for the treatment of inflammatory diseases

(pharmacology) A chimeric monoclonal antibody under investigation for the prevention of staphylococcal sepsis in infants with low birth weight.

(pharmacology) A humanized monoclonal antibody used in the prevention of respiratory syncytial virus infections.

A recombinant monoclonal antibody used in the treatment of some cancers

A mixture of monoclonal antibodies that reacts with all cytokeratins

(pharmacology) A human monoclonal antibody used in the treatment of some cancers.

(pharmacology) A monoclonal antibody designed as an antibacterial against Pseudomonas aeruginosa.

(pharmacology) A humanized monoclonal antibody designed to treat asthma.

(pharmacology) A human monoclonal antibody designed for the treatment of cancer

(pharmacology) A drug that targets the programmed cell death 1 (PD-1) receptor, intended for use in treating metastatic melanoma.

A mouse monoclonal antibody used to treat cancer.

(pharmacology) A humanized monoclonal antibody designed for the treatment of arthritis.

(pharmacology) A monoclonal antibody being developed as a drug to slow tumour growth.

(pharmacology) A humanized monoclonal antibody designed to reduce side effects of cardiac surgery.

(pharmacology) A particular monoclonal antibody.

(pharmacology) An immunomodulating agent used in the treatment of atopic dermatitis.

A mouse monoclonal antibody for the imaging of adenocarcinoma.

(medicine) A derivative of thalidomide used to treat some myelomas

A medication for the treatment of multiple sclerosis.

(pharmacology) A humanized monoclonal antibody designed for the treatment of Alzheimer's disease.

A particular monoclonal antibody

(pharmacology) A chimeric monoclonal antibody designed to treat Crohn's disease and multiple sclerosis.

(pharmacology) A human monoclonal antibody used in treating brain cancer.

(medicine) The EPOCH chemotherapy regimen when supplemented with rituximab.

(pharmacology) A monoclonal antibody for the prophylaxis of rabies.

(pharmacology) A monoclonal antibody used in the treatment of solid tumours.

(pharmacology) A monoclonal antibody fragment derived from the same parent murine antibody as bevacizumab, used as an antiangiogenic.

(pharmacology) A particular monoclonal antibody.

(pharmacology) A human monoclonal antibody intended for the prophylaxis and treatment of inhaled anthrax.

(pharmacology) A human monoclonal antibody against cytomegalovirus infections.

A monoclonal antibody designed for the treatment of melanoma.

(pharmacology) A humanized monoclonal antibody under investigation for the treatment of eosinophil-meditated inflammations of the airways, skin and gastrointestinal tract.

A particular monoclonal antibody

A monoclonal antibody used to treat psoriasis and similar conditions

(medicine, colloquial) Rituximab.

(pharmacology) A chimeric monoclonal antibody (trademark Rituxan) administered by intravenous injection especially to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia by binding to the protein CD20 found on the surface of B cells and causing their lysis.

(pharmacology) A monoclonal antibody and antineoplastic.

An antibody used to treat osteoporosis

(pharmacology) A humanized monoclonal antibody being investigated for the treatment of systemic lupus erythematosus.

(pharmacology) A humanized monoclonal antibody that was an experimental immunosuppressive drug intended to treat patients suffering from haemorrhagic shock by suppressing white blood cells.

(pharmacology) Abbreviation of rituximab. [(pharmacology) A chimeric monoclonal antibody (trademark Rituxan) administered by intravenous injection especially to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia by binding to the protein CD20 found on the surface of B cells and causing their lysis.]

(pharmacology) A humanized monoclonal antibody intended for the treatment of rheumatic diseases.

An antibody and topoisomerase inhibitor drug conjugate for the treatment of some forms of triple negative breast cancer.

(pharmacology) A humanized monoclonal antibody designed for oncology indications.

(pharmacology) A human monoclonal antibody against the interleukin-6 receptor.

A particular monoclonal antibody

A monoclonal antibody containing radiolutetium

A medication for the treatment of neuromyelitis optica spectrum disorder.

A mouse monoclonal antibody used for cancer diagnosis.

(pharmacology) A human monoclonal antibody designed for the treatment of uveitis, rheumatoid arthritis, and psoriasis.

A monoclonal antibody that binds to cell surface proteins

(pharmacology) A human monoclonal antibody used to treat cytomegalovirus infections in AIDS patients.

(pharmacology) A humanized monoclonal antibody intended for the treatment of cancer.

(pharmacology) A human monoclonal antibody designed for the treatment of SLE, dermatomyositis, and polymyositis.

(pharmacology) A monoclonal antibody and antineoplastic.

(pharmacology) A humanized monoclonal antibody designed for the treatment of fibrosis by binding to LOXL2 and acting as an immunomodulator.

A particular monoclonal antibody

(pharmacology) A monoclonal antibody under investigation as a treatment for psoriasis and in the prevention of graft-versus-host disease.

A therapeutic cancer vaccine for prostate cancer.

(pharmacology) A human monoclonal antibody designed for the treatment of rheumatoid arthritis.

(pharmacology) A monoclonal antibody being investigated as a neuroprotector for patients with Alzheimer's disease.

A particular monoclonal antibody

A humanized monoclonal antibody.

An immunoconjugate formed from a human monoclonal antibody

(medicine) A monoclonal antibody used to treat COVID-19

A monoclonal antibody used to treat psoriasis and similar conditions

(pharmacology) An experimental myostatin-inhibiting drug intended to treat Duchenne muscular dystrophy.

A particular mouse monoclonal antibody.

A monoclonal antibody used to treat adults with cold agglutinin disease.

(pharmacology) An antiviral and immunomodulator.

A human monoclonal antibody used to treat pneumonia

Acronym of synthetic antibody mimic.

(pharmacology) A human monoclonal antibody designed for the treatment of autoimmune diseases and B cell malignancies.

(pharmacology) A particular immunological agent.

(pharmacology) A humanized monoclonal antibody that acts on the cardiovascular system, designed for the treatment of patients undergoing percutaneous coronary interventions.

A medication used in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

A particular humanized monoclonal antibody used against myeloid leukemia

(pharmacology) A humanized monoclonal antibody designed to target immunoglobulin E.

(pharmacology) A monoclonal antibody against nerve growth factor, used as a treatment for pain.

A mouse monoclonal antibody intended to be used in treating cancer.

A human bispecific monoclonal antibody used for the treatment of relapsed and refractory multiple myeloma.

(pharmacology) A humanized monoclonal antibody for the treatment of severe infections with Staphylococcus aureus bacteria.

A mouse monoclonal antibody which is an immunosuppressive drug.

A monoclonal antibody designed to treat cancer.

(pharmacology) A chimeric monoclonal antibody that binds to the immune-stimulatory protein CD40.

(pharmacology) A monoclonal antibody used as an immunosuppressive drug.

A human monoclonal antibody used to treat asthma

(former name) tremelimumab.

(pharmacology) A monoclonal antibody for the treatment of cancer.

(pharmacology) An anti-CD19 CAR-T cell therapy used in the treatment of haematological malignancies.

(pharmacology) A particular monoclonal antibody.

A monoclonal antibody against tissue factor.

An antibody-drug conjugate, a combination of tisotumab and monomethyl auristatin E, used to treat cervical cancer.

A monoclonal antibody used to control coronavirus infection

(pharmacology) A humanized monoclonal antibody used as an immunosuppressive drug.

(pharmacology) A humanized monoclonal antibody and immunosuppressive drug, withdrawn because of the risk of thromboembolisms.

A particular monoclonal antibody

A mouse monoclonal antibody intended to treat follicular lymphoma.

Alternative form of tocilizumab [(pharmacology) A humanized monoclonal antibody used as an immunosuppressive drug.]

(pharmacology) A human monoclonal antibody targeting interleukin 13, designed for the treatment of asthma and inflammatory diseases.

(pharmacology) A drug used in the treatment of breast cancer which targets the HER-2 oncogene.

(pharmacology) An immunomodulator drug.

(pharmacology) A human monoclonal antibody that binds to the protein CTLA-4, under investigation to treat various kinds of tumour.

(medicine) A polyclonal antibody for the treatment of COVID-19

(pharmacology) A humanized monoclonal antibody.

(pharmacology) A monoclonal antibody being investigated for the treatment of chronic hepatitis B.

A particular immunomodulator.

An oral medication for the treatment of marginal zone lymphoma and follicular lymphoma.

(pharmacology) A humanized monoclonal antibody used to treat diarrhoea caused by Escherichia coli.

(pharmacology) A human monoclonal antibody directed against interleukin 12 and interleukin 23, in clinical trials for multiple sclerosis, psoriasis, and psoriatic arthritis.

A particular monoclonal antibody

(pharmacology) A chimeric monoclonal antibody used as an immunosuppressive drug.

(pharmacology) A monoclonal antibody under investigation for the treatment of ulcerative colitis and Crohn's disease.

(pharmacology) A monoclonal antibody under investigation for the treatment of non-Hodgkin lymphoma.

(pharmacology) A mouse monoclonal antibody used to treat inflammations.

(pharmacology) A humanized monoclonal antibody being investigated for use as an immunosuppressive drug in patients with ulcerative colitis and Crohn's disease.

A monoclonal antibody proposed for the treatment of inflammatory autoimmune disease

(pharmacology) A chimeric monoclonal antibody used to treat various solid tumours.

(pharmacology) A human monoclonal antibody used to detect colorectal tumours.

(pharmacology) A human monoclonal antibody designed for the treatment of cancer of the head and neck.

(pharmacology) A human monoclonal antibody and immunosuppressive drug.

A particular monoclonal antibody

A particular monoclonal antibody

A particular mouse monoclonal antibody.

(pharmacology) An immunosuppressant, a semisynthetic derivative of rapamycin.